CN1585768A - 作为精神药物的吡唑衍生物 - Google Patents

作为精神药物的吡唑衍生物 Download PDF

Info

Publication number
CN1585768A
CN1585768A CNA02822566XA CN02822566A CN1585768A CN 1585768 A CN1585768 A CN 1585768A CN A02822566X A CNA02822566X A CN A02822566XA CN 02822566 A CN02822566 A CN 02822566A CN 1585768 A CN1585768 A CN 1585768A
Authority
CN
China
Prior art keywords
methyl
formula
compounds
solvates
physiologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA02822566XA
Other languages
English (en)
Chinese (zh)
Inventor
H·布特彻尔
C·赛福里德
C·范阿姆斯特丹
G·巴托茨克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN1585768A publication Critical patent/CN1585768A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA02822566XA 2001-11-14 2002-10-14 作为精神药物的吡唑衍生物 Pending CN1585768A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01126531.1 2001-11-14
EP01126531 2001-11-14

Publications (1)

Publication Number Publication Date
CN1585768A true CN1585768A (zh) 2005-02-23

Family

ID=8179188

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA02822566XA Pending CN1585768A (zh) 2001-11-14 2002-10-14 作为精神药物的吡唑衍生物

Country Status (11)

Country Link
US (1) US20050026927A1 (https=)
EP (1) EP1444229A1 (https=)
JP (1) JP2005511625A (https=)
KR (1) KR20050036882A (https=)
CN (1) CN1585768A (https=)
BR (1) BR0214046A (https=)
CA (1) CA2467081A1 (https=)
HU (1) HUP0402124A2 (https=)
MX (1) MXPA04004443A (https=)
PL (1) PL369674A1 (https=)
WO (1) WO2003042208A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104854175A (zh) * 2012-12-18 2015-08-19 默克专利股份有限公司 包含噻二唑基的聚合物、这种聚合物的制备和它在有机电子器件中的用途
WO2024124439A1 (zh) * 2022-12-14 2024-06-20 苏州大学 一种抗菌抗肿瘤增效剂及其合成方法与应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320320D0 (en) * 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
GB0321473D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
WO2006002284A1 (en) * 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2012074853A1 (en) 2010-11-22 2012-06-07 The Regents Of The University Of California Organic small molecule semiconducting chromophores for use in organic electronic devices
ES2707886T3 (es) 2012-02-14 2019-04-05 Next Energy Tech Inc Dispositivos electrónicos que usan compuestos semiconductores orgánicos de molécula pequeña
US9865821B2 (en) * 2012-02-17 2018-01-09 Next Energy Technologies, Inc. Organic semiconducting compounds for use in organic electronic devices
CN104768949A (zh) * 2012-08-24 2015-07-08 特温蒂斯公司 苯并呋咱抗淀粉样蛋白化合物和方法
JP6663361B2 (ja) * 2014-02-27 2020-03-11 トレヴェンティス コーポレーション ベンゾフラザンを含有する抗アミロイド化合物
CA3005766A1 (en) 2015-12-17 2017-06-22 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
JP7125385B2 (ja) 2016-08-08 2022-08-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｌｒ７／８アンタゴニストおよびそれらの使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6517196A (en) * 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
DE19602505A1 (de) * 1996-01-25 1997-07-31 Merck Patent Gmbh 1-(Pyrazol-4-Indol-3-yl)-Piperidine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104854175A (zh) * 2012-12-18 2015-08-19 默克专利股份有限公司 包含噻二唑基的聚合物、这种聚合物的制备和它在有机电子器件中的用途
WO2024124439A1 (zh) * 2022-12-14 2024-06-20 苏州大学 一种抗菌抗肿瘤增效剂及其合成方法与应用

Also Published As

Publication number Publication date
PL369674A1 (en) 2005-05-02
KR20050036882A (ko) 2005-04-20
MXPA04004443A (es) 2004-08-11
HUP0402124A2 (hu) 2005-02-28
BR0214046A (pt) 2004-10-13
EP1444229A1 (en) 2004-08-11
CA2467081A1 (en) 2003-05-22
JP2005511625A (ja) 2005-04-28
WO2003042208A1 (en) 2003-05-22
US20050026927A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
CN1128139C (zh) 新哌嗪衍生物及其制造方法
CN1324015C (zh) 吡啶－和嘧啶－衍生物
CN1110495C (zh) 芳烷基二嗪酮，其制备方法及其药物制剂
CN1109057A (zh) 咪唑并哒嗪
CN1556705A (zh) 7,8,9,10-四氢-6H-氮杂卓并、6,7,8,9-四氢-吡啶并和2,3-二氢-2H-吡咯并[2,1-b]-喹唑啉酮衍生物
CN1233246A (zh) 氨基噻吩羧基酰胺及其作为磷酸二酯酶抑制剂的用途
CN1079219A (zh) 芳基乙酰胺
CN1642927A (zh) 环状酰胺
CN101056875A (zh) 被取代的苯基氨基噻唑类化合物以及其应用
CN1585768A (zh) 作为精神药物的吡唑衍生物
CN1675188A (zh) 噻唑衍生物
CN1668584A (zh) 作为抗分支杆菌化合物的吡咯衍生物
CN1103534A (zh) 具有抗精神病作用的化合物
CN1571781A (zh) 4－咪唑啉－2－酮化合物
CN1993367A (zh) 稠合的嘧啶衍生物和黄嘌呤氧化酶抑制剂
CN1852907A (zh) 2－氨基－5－苯甲酰基噻唑npy拮抗剂
CN1031754C (zh) 制备二噻烷衍生物的方法
CN1397557A (zh) 新的八氢－2H－吡啶并[1,2－a]吡嗪化合物、它们的制备方法和含有它们的药物组合物
CN1108456A (zh) 苯并噻唑化合物及其制法和用途
CN1276920C (zh) 噻唑烷二酮衍生物以及包含该衍生物的药物组合物
CN1020097C (zh) 取代的苯衍生物的制备方法
CN1882562A (zh) 苯并呋喃和苯并噻吩类化合物
CN1723209A (zh) 吲哚衍生物以及它们作为5－ht配体的应用
HK1087698A (en) Indol derivatives and their use as 5-ht ligands
CN1184969C (zh) 未取代和取代的n－(吡咯－1－基)吡啶胺作为抗惊厥药的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication